← Back to patent-cliff list
[203-Pb] VMT-NET
Tier C — Watch / trade[203-Pb] VMT-NET
Perspective Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：SSTR2
Indications (approved)：Paraganglioma, Neuroendocrine tumour, Phaeochromocytoma, Nasopharyngeal carcinoma, 成感觉神经细胞瘤, 神经胶质瘤, Renal cell carcinoma, Head and neck cancer
Regional status
US
Phase II
2025-02-07
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [203-Pb] VMT-NET?
Approved indications include: Paraganglioma, Neuroendocrine tumour, Phaeochromocytoma, Nasopharyngeal carcinoma, 成感觉神经细胞瘤, 神经胶质瘤, Renal cell carcinoma, Head and neck cancer.
When does the [203-Pb] VMT-NET patent expire?
No public expiry year is available for [203-Pb] VMT-NET yet; this page updates once verified.
How do I get a quote for [203-Pb] VMT-NET intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01